Stockscreener 앱 받기
6.24
54.07%
2.19
시장 영업 전:
5.65
-0.59
-9.46%
Neuphoria Therapeutics Inc 주식(NEUP)의 최신 뉴스
Why hedge funds are buying Neuphoria Therapeutics Inc. stockJuly 2025 Sentiment & Fast Gain Swing Trade Alerts - newser.com
Neuphoria Therapeutics Inc.’s volatility index tracking explainedPortfolio Performance Report & Consistent Return Investment Signals - newser.com
Can Neuphoria Therapeutics Inc. stock rebound after recent weaknessQuarterly Trade Report & Expert Approved Momentum Ideas - newser.com
Using AI based signals to follow Neuphoria Therapeutics Inc.2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
Why analysts upgrade Neuphoria Therapeutics Inc. stockWeekly Stock Summary & Capital Efficient Trading Techniques - newser.com
Will Neuphoria Therapeutics Inc. stock keep outperforming rivalsPortfolio Value Summary & Expert Verified Movement Alerts - newser.com
Is Neuphoria Therapeutics Inc. stock attractive after correctionSell Signal & AI Powered Market Entry Strategies - newser.com
Can Neuphoria Therapeutics Inc. stock hit analyst price targets2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Automated trading signals detected on Neuphoria Therapeutics Inc.Exit Point & Momentum Based Trading Ideas - newser.com
How Neuphoria Therapeutics Inc. stock performs in interest rate cyclesTrade Entry Summary & Weekly High Momentum Picks - newser.com
Best Biotech Stocks To Keep An Eye OnOctober 25th - MarketBeat
Published on: 2025-10-26 11:08:10 - newser.com
Published on: 2025-10-26 10:45:26 - newser.com
Neuphoria Therapeutics Advances BNC-210 Trial with Prolonged Cash Runway - StocksToTrade
Neuphoria Therapeutics Phase 3 Trial Progress Spurs Investor Optimism - timothysykes.com
Published on: 2025-10-26 11:32:54 - newser.com
Can Neuphoria Therapeutics Inc. stock maintain operating marginsJuly 2025 PostEarnings & Precise Buy Zone Identification - newser.com
Published on: 2025-10-25 19:04:06 - newser.com
Neuphoria Therapeutics Stock Gains Amid Phase 3 Trial Advances - StocksToTrade
Neuphoria Therapeutics Advances Social Anxiety Drug in Key Phase 3 Trial - timothysykes.com
1.11%
0.29%
자본화:
|
볼륨(24시간):